EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Levosimendan: A Novel Agent in Heart Failure

Nikolas Koumallos, Charalambos Antoniades, Dimitris Tousoulis, Cheerag Shirodaria, Christodoulos Stefanadis

Recent Patents on Cardiovascular Drug Discovery · 2006

DOI: 10.2174/157489006777442487 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Recent Patents on Cardiovascular Drug Discovery, 2006. Verfasst von Nikolas Koumallos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Athens University Medical School, A Cardiology Department, Athens, Greece. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure is characterised by decreased cardiac output, which results in the development of both peripheral hypoperfusion and pulmonary congestion and can lead to the development of acute pulmonary edema. The primary objective in treating a patient with decompensated heart failure is hemodynamic stabilization, which is usually achieved by inotropic support. Classic inotropic agents provide short-term hemodynamic improvement, but their use has been correlated with poor prognosis. Levosimendan, a new calcium sensitizer, offers hemodynamic and symptomatic improvement without increasing cAMP and intracellular calcium concentrations. This agent improves contractility without increasing the risk of cardiac events such as arrhythmias. By combining a positive inotropic action mediated via calcium sensitization and a vasodilatory effect via ATP-dependent potassium channels, it appears to be superior than classic positive inotropic agents. Furthermore, it seems to have prolonged benefit in heart failure patients, and it also has anti-inflammatory and antiapoptotic properties. In conclusion, levosimendan seems to be a particularly promising agent for the treatment of decompensated heart failure, as in addition to improving cardiac output, it has a more favorable side-effect profile than classic inotropic agents, and it affects multiple pathways with key role in the pathophysiology of heart failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsApoptosisCardiotonic AgentsHeart FailureHemodynamicsHumansHydrazonesPyridazinesSimendanVasodilator Agents

Substanzen

Cardiotonic AgentsHydrazonesPyridazinesVasodilator AgentsSimendan

Autor:innen und Institutionen

  • Athens University Medical School, A Cardiology Department, Athens, Greece.

Zitieren

APA

Koumallos, N., Antoniades, C., Tousoulis, D., Shirodaria, C., & Stefanadis, C. (2006). Levosimendan: A Novel Agent in Heart Failure. Recent Patents on Cardiovascular Drug Discovery. https://doi.org/10.2174/157489006777442487

Vancouver

Koumallos N, Antoniades C, Tousoulis D, Shirodaria C, Stefanadis C. Levosimendan: A Novel Agent in Heart Failure. Recent Patents on Cardiovascular Drug Discovery. 2006. doi:10.2174/157489006777442487

BibTeX
@article{Koumallos2006,
  author = {Koumallos, Nikolas and Antoniades, Charalambos and Tousoulis, Dimitris and Shirodaria, Cheerag and Stefanadis, Christodoulos},
  title = {Levosimendan: A Novel Agent in Heart Failure},
  journal = {Recent Patents on Cardiovascular Drug Discovery},
  year = {2006},
  doi = {10.2174/157489006777442487}
}
Kostenlos starten →